- Home
- PLX vs CHN Comparison
PLX vs CHN Comparison
Compare PLX & CHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- CHN
- Stock Information
- Founded
- PLX 1993
- CHN 1992
- Country
- PLX Israel
- CHN United States
- Employees
- PLX N/A
- CHN N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- CHN Investment Managers
- Sector
- PLX Health Care
- CHN Finance
- Exchange
- PLX Nasdaq
- CHN Nasdaq
- Market Cap
- PLX 160.2M
- CHN 128.4M
- IPO Year
- PLX 1998
- CHN N/A
- Fundamental
- Price
- PLX $2.59
- CHN $12.75
- Analyst Decision
- PLX Strong Buy
- CHN
- Analyst Count
- PLX 1
- CHN 0
- Target Price
- PLX $15.00
- CHN N/A
- AVG Volume (30 Days)
- PLX 764.3K
- CHN 31.8K
- Earning Date
- PLX 03-17-2025
- CHN 01-01-0001
- Dividend Yield
- PLX N/A
- CHN 0.19%
- EPS Growth
- PLX N/A
- CHN N/A
- EPS
- PLX 0.04
- CHN N/A
- Revenue
- PLX $53,399,000.00
- CHN N/A
- Revenue This Year
- PLX $67.17
- CHN N/A
- Revenue Next Year
- PLX $55.31
- CHN N/A
- P/E Ratio
- PLX $71.07
- CHN N/A
- Revenue Growth
- PLX N/A
- CHN N/A
- 52 Week Low
- PLX $0.82
- CHN $9.00
- 52 Week High
- PLX $2.76
- CHN $12.98
- Technical
- Relative Strength Index (RSI)
- PLX 58.97
- CHN 43.27
- Support Level
- PLX $2.43
- CHN $13.00
- Resistance Level
- PLX $2.62
- CHN $13.30
- Average True Range (ATR)
- PLX 0.14
- CHN 0.25
- MACD
- PLX 0.02
- CHN -0.12
- Stochastic Oscillator
- PLX 85.00
- CHN 5.00
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.